MASH Updates: Sagimet, Altimmune, GSK Discuss Development Plans At AASLD

 
• By Joseph Haas
  
AASLD 2025 - The Liver Meeting
Multiple companies provided updates on their MASH R&D plans at AASLD 2025 (Joseph Haas/Citeline)

More from Strategy

More from Business